The ARC leadership team is deeply committed to amyloidosis and work tirelessly to deliver our programs which are fully integrated across the entire research and development continuum and into the clinic. These closely align with our mission, and focus on the areas that are most important, can best be delivered by ARC and most likely to have the biggest impact on patients, short and long-term.



Isabelle Lousada, President & CEO

Isabelle Lousada has been the driving force behind ARC, building successful collaborations and programs across the sectors to advance the science and understanding of the amyloidosis diseases.

Isabelle was diagnosed with AL amyloidosis, and was one of the first patients to successfully undergo a stem cell transplant.  For the past twenty years, she has been committed to empowering other patients while serving on a number of boards and committees, speaking at leadership meetings and key events to encourage research, increase access, and support the critical and unmet needs of amyloidosis patients.

Sarah Cairns-Smith, Chairman, ARC

Sarah is a senior partner and managing director at The Boston Consulting Group. She is based in Boston where she leads BCG's scientist network (over 250 life science MDs and PhDs). She focuses on innovation topics across public, social and private sectors – both within health care and beyond. 



Eric Low, OBE, Chairman, ARC-UK

Eric joined as the Chairman of ARC-UK. Over the past 20 years Eric, while at the helm of Myeloma UK, an Internationally renowned non-profit, has committed more funding than any other organization to amyloidosis research. His expertise, keen interest in ensuring patients have access to treatment, and visionary work will catalyze the ARC’s programs to accelerate drug development.


Monica Morris

Kristen Hsu, Executive Director of Clinical Research

Kristen has over ten years of clinical operations experience within the pharmaceutical industry. She has a wealth of experience in managing complex global clinical trials for novel treatments of rare diseases. Kristen is building and overseeing the ARC’s clinical research program and manages a prioritized portfolio of vital research.


Monica Morris, Director of Healthcare Professional and Patient Programs

Monica is a hematology nurse with over 25 years of experience in amyloidosis.  During her career she has worked clinically as a specialist nurse, and within non-profits, developing and providing information and education resources for patients and HCPs. Monica is leading the expansion of ARC's patient information, awareness and HCP education programs.



Sara Brookes, Communication and Marketing Manager

Robyn Himick, Clinical Trial Manager

Maggie Lai, Scientific and Medical Communications Manager

Sarah Richard, Market Access and Health Services Manager

Mary Ellen Thomas, Executive Operations Officer

Melissa Warner, Research Associate

Board of Directors

Sarah Cairns-Smith, Board Chairman, Senior Partner and Managing Director Boston Consulting Group 

Raymond Comenzo, MD, Director, Blood Bank and Stem Cell Processing Laboratory; Professor, Tufts University School of Medicine 

Dena Heath, Board Secretary, Facilitator, Northern California Amyloidosis Support Group

Isabelle Lousada, CEO, Amyloidosis Research Consortium

Giampaolo Merlini, MD, Director of the Center for Research and Treatment of Systemic Amyloidosis, and of the Biotechnology Research Laboratories, Scientific Institute Policlinico San Matteo, University of Pavia, Italy 

Jason Shore, Board Treasurer, CEO, Patient Discovery

Steering Committee 

A multidisciplinary team of experts in the field of amyloidosis oversees the ARC’s scientific agenda and strategic direction.

Angela Dispenzieri MD, Mayo Clinic

Raymond Comenzo MD, Tufts Medical School

Eric Low OBE, Chairman, ARC-UK

Jeffery Kelly PhD, Scripps Research Institute

Mathew Maurer MD, New York-Presbyterian Hospital

Giampaolo Merlini MD, University of Pavia

Vaishali Sanchorawala MD, Boston Medical Center

Ashutosh Wechalekar MD, Royal Free Hospital